Breakthroughs in Diagnosing Prostate Cancer

Carolyn Fronczak, MD, MSPH Urologist, Boulder Medical Center 303-731-3674

Stephen Siegel, MD Urologist, Boulder Medical Center 303-997-3624





Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis Gleason score, Grade, Stage
- Treatment Options











MULTIDISCIPLINARY APPROACH



Multidisciplinary Approach



- Urologists
- Radiation oncologists
- Medical oncologists
- Radiologists
- Genetic testing and counseling



Multidisciplinary Approach



- Significant Benefits
 - Improved outcomes
 - Shared decision making
 - More patient satisfaction with treatment decision
 - Offer multimodal therapies



Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis-Gleason score, Grade, Stage
- Treatment Options



Prostate Cancer



#1 cancer





			Males
Prostate	248,530	26%	
Lung & bronchus	119,100	12%	
Colon & rectum	79,520	8%	
Urinary bladder	64,280	7%	
Melanoma of the skin	62,260	6%	
Kidney & renal pelvis	48,780	5%	
Non-Hodgkin lymphoma	45,630	5%	
Oral cavity & pharynx	38,800	4%	
Leukemia	35,530	4%	
Pancreas	31,950	3%	
All Sites	970,250	100%	

Estimated Deaths

			Maico
Lung & bronchus	69,410	22%	
Prostate	34,130	11%	>, (
Colon & rectum	28,520	9%	
Pancreas	25,270	8%	
Liver & intrahepatic bile duct	20,300	6%	
Leukemia	13,900	4%	
Esophagus	12,410	4%	
Urinary bladder	12,260	4%	
Non-Hodgkin lymphoma	12,170	4%	
Brain & other nervous system	10,500	3%	
All Sites	319,420	100%	

Siegel RL, CA Cancer J Clin. 2021 Jan;71:7-33.



Risk Factors



- Male gender and older age
- Family history
 - Father w prostate ca 2x more likely
 - Brother w prostate ca 4x more likely
 - Father and brother w prostate ca 8x more likely
- Ethnicity
 - African Americans 1.6 x more likely to have disease
 - Americans 2.2 x more likely to die of disease



Risk Factors




- Family history
- Cancers
 - Metastatic prostate cancer
 - Ovarian cancer
 - Male or female breast cancer
 - Colorectal
 - Endometrial cancer
 - Pancreatic cancer
- Ashkenazi Jewish ancestry
- Multiple cancers in family



Risk Factors



- Germline mutations
- BRACA2
- 11.8% metastatic prostate cancer
- 6% localized high-risk prostate cancer
- 2% low-to-intermediate-risk prostate cancer
- Future = targeted treatment using PARP inhibitors





Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options



What is the PSA?



- Prostate specific antigen (PSA)
- PSA is a blood test.
- Measures the amount of PSA in the blood stream.
- Secreted by normal and abnormal prostate cells.




PSA not a prostate cancer-specific marker




- PSA can be higher in prostate cancer but also in:
 - Large prostates = Benign Prostate Hyperplasia (BPH)
 - Infections (prostatitis, urinary tract infections, epididymitis)
 - Recent ejaculation
 - Trauma
 - Recent urinary catheterization
 - Recent biking



History of PSA and **Prostate Cancer**




Mortality from Prostate Cancer



US Preventative Task Force 2008-2012




- Discouraged use of PSA
- Task force
 - Panel of 16 experts:
 - -family medicine, general internal medicine, nurses, obstetrician-gynecologists, occupational medicine physicians, and pediatricians.
 - PANEL DID NOT INCLUDE UROLOGISTS OR CANCER SPECIALISTS





Incidence of Prostate Cancer



Outcome from Task Force



MORE DEATHS FROM PROSTATE CANCER

Prostate cancer **DEATHS INCREASED** in 2018 for the first time in 2 decades from an estimated 26,730 in 2017 to 29,430 in 2018.


For 2022, the estimate is 34,500 deaths from prostate cancer.



Revised Task Force Recommendations



- For men >70yrs
 - USPTF continues to recommend against PSA testing.
 - SHARED DECISION MAKING









PSA Screening Recommendations



Age < 40

No reason to screen.

Ages 40 - 54

- No screening if at "average risk" but you should be screened if:
 - A family history of a first degree relative (sibling or parent) with prostate, breast, ovarian or pancreatic cancer
 - African-American

Ages 55 - 69

 This is the age group where screening is most important. This should be a shared discussion with your physician.



PSA Screening Recommendations



Ages > 70

- Continue screening if you are in excellent health with a 10-15 year life expectancy, otherwise no screening is necessary.
- This should be a shared discussion with your physician.
- According to the American Cancer Society, if your PSA is:
 - less than 2.5, you can have your blood tested every four years
 - greater than 2.5, it should be done every two years



Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options



Individualized Decision Making



- Maximize detection of lethal prostate cancer in a patient with life expectancy of greater than 10 -15yrs
- Accurately characterize the biology of the tumor
- Risk stratification of the cancer
 - Minimize immediate treatment (over-treatment) of indolent cancers.
 - Proceed with treatment of potentially lethal prostate cancers.



Initial evaluation



- Digital rectal exam (DRE) + PSA
- A DRE should be done in all men with an abnormal PSA.
- If abnormal DRE and elevated PSA
 - Positive predictive value for prostate cancer is 48.6% vs 22.4% for men elevated PSA and a normal DRE.
- Only 25% of men with PSA 4-10 ng/mL have a subsequent positive biopsy.
- If a new high PSA is observed, then repeat the test.
 - 5 days pelvic rest prior to test and at least 1 month from last PSA



Abnormal DRE, normal PSA



- Some prostate cancers do not make PSA.
- Positive predicative value of an abnormal DRE in men with normal PSA only 4%–21%.
- BUT an abnormal DRE should be evaluated!!



Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis-Gleason score, Grade, Stage
- Treatment Options



Noninvasive Pre-diagnostic Testing



- Men (and their urologist) want to avoid a biopsy if possible.
- A prostate biopsy is still considered "gold standard".
- BUT noninvasive options to determine if a biopsy is needed are always discussed.

Goal - NOT just find prostate cancer, but find potentially <u>lethal</u> prostate cancer.



Prostate MRI



- Multiparametric (mp) MRI of the prostate
 - Anatomic evaluation a "window" into the prostate
- Benefits
 - Characterize suspicious lesions felt on DRE
 - Evaluate elevated PSA to help decide on the need for biopsy
 - Perform targeted biopsy of a suspicious lesion
 - Reduced biopsy rate of benign tissue (PIRAD1 and PIRAD2 tissue)
 - Reduce the identification of low-risk prostate cancer by 87%
 - Increase finding intermediate/high-risk tumors by 18%
 - Active surveillance to follow lesions



mpMRI PI-RADS score




Prostate Imaging – Reporting and Data System version 2

PI-RADS classification	Definition	Total T2 + DWI + DCE score	Total T2 + DWI + DCE + MRS score	
1	Most probably benign	3 - 4	4 - 5	
II	Probably benign	5 - 6	6 - 8	
III	Indeterminate	7 - 9	9 - 12	
IV	Probably malignant	10 - 12	13 – 15	
V	Most probably malignant	13 - 15	17 - 20	
PI-RAD IV and V should have targeted biopsy				




MRI Fusion Biopsy Set Up



MRI Fusion Biopsy Completed








Prostate MRI



- Not perfect (no test is)
- MRI before biopsy approach could miss 24% of potentially lethal prostate cancers.
- Interobserver variability
 - One radiologist scores prostate lesions one way and another radiologist scores the lesion another way.
 - Boulder Community Health radiologists read all our scans
 - Two Boulder Community Health radiologists often read each MRI



Prostate Biopsy Technique





Comparison	Transrectal	Transperineal
Infection	0.38-4.2%	0.6-1.03%
Urinary obstruction (need for foley)	0-0.8%	0.5-7.9%
Need for anxiolytic (valium)	NO	YES
Need for general or spinal anesthesia	NO	YES
Accuracy of detecting prostate cancer	Same	Same
Cost	Less expensive	More expensive

Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options




Why is Genomic Testing Important?



NGS

Disease State Biomarkers (partial list)





4Kscore



- Algorithm patient's age, family history, race, digital rectal exam, and previous biopsy status
- Panel of 4 known markers
 - total PSA
 - free PSA
 - intact PSA
 - hK2
- Gives percent likelihood of finding potentially lethal cancer on biopsy
- Biopsies can be avoided, high grade cancer detected, but 5-10% cancers are missed in reported trials



SelectMDx



- Urine assay for RNA
- Urine collected after digital rectal exam
- DLX1 and HOXC6 mRNA
- Has a 95% negative predictive value and 93% sensitivity for the detection of clinically significant prostate cancer
 - Translation if low risk result, then highly likely there is no cancer, and the test has good accuracy for determining if there is cancer.
- Reduces the number of unnecessary biopsies
 - 53% prostate biopsies can be avoided



ExoDX



- Urinary exosomal RNA
- No DRE required
- For high-grade disease:
 - Excellent negative predictive value of 97.5% (if low risk, then 97.5% chance there is no cancer)



ConfirmDx



- If prostate biopsy comes back benign, can do additional genetic testing with ConfirmDx.
- Hypermethylation of the promoter regions of GSTP1, APC, and RASSF1 is assessed in core biopsy tissue samples.
- Improve the stratification of men with prior negative biopsy being considered for repeat prostate biopsy.
 - Who needs to be followed more aggressively?



Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options



Additional Evaluations



• If no cancer found or low grade prostate cancer found and the man has bothersome urinary symptoms.



Bothersome Urinary Symptoms



- Evaluate urinary retention
- Evaluate bladder health



- Discuss medical vs surgical intervention
- Discuss minimally invasive treatment options



International Prostate Symptom Score (I-PSS)

Patient Name: Date of birth: Date completed

In the past month:	Not at All	Less than 1 in 5 Times	Less than Half the Time	About Half the Time	More than Half the Time	Almost Always	Your score
1. Incomplete Emptying How often have you had the sensation of not emptying your bladder?	0	1	2	3	4	5	
2. Frequency How often have you had to urinate less than every two hours?	0	1	2	3	4	5	
3. Intermittency How often have you found you stopped and started again several times when you urinated?	0	1	2	3	4	5	
4. Urgency How often have you found it difficult to postpone urination?	0	1	2	3	4	5	
5. Weak Stream How often have you had a weak urinary stream?	0	1	2	3	4	5	
6. Straining How often have you had to strain to start urination?	0	1	2	3	4	5	
	None	1 Time	2 Times	3 Times	4 Times	5 Times	
7. Nocturia How many times did you typically get up at night to urinate?	0	1	2	3	4	5	
Total I-PSS Score							27

Score:

1-7: Mild


8-19: Modera

20-35: Severe

Quality of Life Due to Urinary Symptoms	Delighted	Pleased	Mostly Satisfied	Mixed	Mostly Dissatisfied	Unhappy	Terrible
If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?	0	1	2	3	4	5	6

Urolift Center of Excellence





Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options




Prostate Cancer Grading




Gleason score







Grade group



Prostate Cancer Risk Stratification

	AUA Risk Category	NCCN Risk Category
Very Low		PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stageT1c, < 3 positive biopsy cores, ≤ 50% in each core, and PSA density < 0.15 ng/mL/g
Low	PSA ≤ 10 ng/mL, Gleason score ≤ 6, and clinical stageT1c or T2a	PSA < 10 ng/mL, Gleason score ≤ 6, and clinical stageT1-T2a
Intermediate	PSA > 10-20ng/mL or Gleason score 7, or clinical stage T2b	PSA 10-20 ng/mL, Gleason score 7, or clinical stageT2b-T2c
High	PSA > 20ng/mL or Gleason score 8-10, or clinical stage ≥T2c	PSA > 20ng/mL or Gleason score 8- 10, or clinical stage T3a
Very High		Clinical stage T3b-T4

Prostate Cancer Risk Stratification

	AUA Risk Category	NCCN Risk Category
Very Low	_	PSA ≤ 10 ng/mL, Gleason score ≤ 6, clinical stageT1c, < 3 positive biopsy cores, ≤ 50% in each core, and PSA density < 0.15 ng/mL/g
Low	PSA ≤ 10 ng/mL, Gleason score ≤ 6, and clinical stageT1c or T2a	PSA < 10 ng/mL, Gleason score ≤ 6, and clinical stageT1-T2a
Intermediate	PSA > 10-20ng/mL or Gleason score 7, or clinical stage T2b	PSA 10-20 ng/mL, Gleason score 7, or clinical stageT2b-T2c
High	PSA > 20ng/mL or Gleason score 8-10, or clinical stage ≥T2c	PSA > 20ng/mL or Gleason score 8- 10, or clinical stage T3a
Very High	_	Clinical stage T3b-T4

New Prostate Cancer Diagnosis



- Genomics adds helpful information
- Each tumor is unique
- What is the REAL RISK of harm by not doing treatment?
- Can you wait and follow the tumor and decide later to do treatment?
- Tumors can get upstaged or downstaged
- Overall survival is "gold standard".....BUT...



New Prostate Cancer Diagnosis



 Metastasis free survival is the STRONGEST surrogate for OVERALL survival in localized prostate cancer.

J Clin Oncol 35, 3097-3104, doi:10.1200/JCO.2017.73.9987 (2017)



Decipher



- Genomic test.
- Predicts metastasis in a prostate biopsy.
- Use RNA, 22 genes across 7 cancer pathways.
- Divides the results into high, intermediate, and low risk category.
- DECIPHER outperforms all other clinical risk factors for predicting metastasis
 - Better than PSA, stage, Gleason score, NCCN risk categories




CLINICAL AND PATHOLOGY DETAILS For reference only, not used in calculation of genomic risk

Specimen: Needle Biopsy Most Recent PSA: 4.9 ng/mL NCCN Risk Category: Intermediate

Clinical Stage: T1c Gleason Score: 3+4

DECIPHER GENOMIC RISK RESULTS



GENOMIC RISK IS: LOW						
0.5%	0.5% 1.2% 2.4% 14.6%					
5-year	10-year	15-year	At RP			
Risk of Metastasis with RT† or RP‡						

Clinical studies have shown that Decipher low-risk patients have a favorable prognosis.

- These patients may be ideal candidates for active surveillance.^{1-3,6}
- Patients considering definitive treatment may have excellent oncologic outcomes when treated with local therapy alone.^{2-5,9}

The Decipher score is determined solely by genomic characteristics of the tumor, independent of the NCCN risk category. No other clinical or pathologic parameters factor into the score.


CLINICAL AND PATHOLOGY DETAILS For reference only, not used in calculation of genomic risk

Specimen: Needle Biopsy Most Recent PSA: 4.9 ng/mL

Clinical Stage: T1c Gleason Score: 3+4

NCCN Risk Category: Intermediate

DECIPHER GENOMIC RISK RESULTS



GENOMIC RISK IS: INTERMEDIATE				
1.1% 2.7% 4.6% 28.4%				
5-year	10-year	15-year	At RP	
	Risk of Metastasis with RT [†] or RP [‡] Risk of Prostate Cancer Mortality with RT or RP		Risk of Adverse Pathology	

Clinical studies have shown that Decipher intermediate-risk patients have an average clinical risk and prognosis. Depending on life expectancy and overall health status:

- These patients may not be ideal candidates for active surveillance.^{1-3,6}
- These patients may benefit from definitive therapy.^{2-5,9}

The Decipher score is determined solely by genomic characteristics of the tumor, independent of the NCCN risk category. No other clinical or pathologic parameters factor into the score.

CLINICAL AND PATHOLOGY DETAILS For reference only, not used in calculation of genomic risk

Specimen: Needle Biopsy


Most Recent PSA: 4.9 ng/mL

NCCN Risk Category: Intermediate

Clinical Stage: T1c

Gleason Score: 3+4

DECIPHER GENOMIC RISK RESULTS



GENOMIC RISK IS: HIGH						
2.6%	2.6% 6.5% 8.8% 48.1%					
5-year	10-year	15-year	At RP			
Risk of Metastasis with RT [†] or RP [‡]						

Clinical studies have shown that Decipher high-risk patients have an unfavorable prognosis.

- These patients may benefit from treatment intensification with multimodal therapy.^{2-5,9,10}
- These patients may not be ideal candidates for active surveillance.^{1-3,8}

The Decipher score is determined solely by genomic characteristics of the tumor, independent of the NCCN risk category. No other clinical or pathologic parameters factor into the score.



- Decipher can also help guide:
 - If treatment with radiation, does patient need radiation treatment along with hormone therapy?
 - And what is the duration of hormone therapy?



Topics to Cover



- Multidisciplinary approach to prostate cancer
- Epidemiology incidence and risk factors
- PSA screening
- Elevated PSA, now what??
- Noninvasive testing before biopsy
 - MRI
 - Genomic markers
- Additional prostate evaluation if no prostate cancer
- Diagnosis- Gleason score, Grade, Stage
- Treatment Options



Which Treatment Option is Right for Me?



Attend the BCH lecture on Tuesday, June 28, 2022

- Dr. Patrick Richard (radiation oncologist)
- Dr. Dario Pasalic (radiation oncologist)
- Dr. Stephen Siegel (urologic surgeon)











MULTIDISCIPLINARY APPROACH

Bolder Boulder 2022







Breakthroughs in Diagnosing Prostate Cancer

Carolyn Fronczak, MD, MSPH Urologic Surgery, Boulder Medical Center 303-731-3674

Stephen Siegel, MD Urologic Surgery, Boulder Medical Center 303-997-3624



